The single dose radiotherapy services market is expected to expand steadily between 2025 and 2035, driven by growing clinical evidence supporting single fraction radiotherapy, rising demand for cost-effective cancer treatments, and technological advances in image-guided radiation delivery.
The market is projected to be valued at USD 9,072.5 million in 2025 and is anticipated to reach USD 18,014.4 million by 2035, reflecting a CAGR of 7.1% over the forecast period.
In single dose radiotherapy, the dose of radiation, a full therapeutic dose, is given in one session, and is also called single fraction radiotherapy. It is to a growing extent used in palliative care, early-stage breast cancer, prostate cancer and bone metastasis.
The method has potential clinical benefits such as shorter treatment schedules and fewer hospital visits and better patient quality of life, making it especially appealing for low-resource settings as well as during pandemics or health crises. Nonetheless, there are still barriers to personalization of treatment, long-term data on efficacy, and access to facilities.
Market Metrics
| Metric | Value (USD) |
|---|---|
| Industry Size (2025E) | USD 9,072.5 million |
| Industry Value (2035F) | USD 18,014.4 million |
| CAGR (2025 to 2035) | 7.1% |
They encompass real-time dose monitoring and delivery control after motion events, as well as ultra-high dose rate (FLASH) radiotherapy, which will improve therapeutic effectiveness while achieving the desired treatment in each session with minimal unwanted events.
Explore FMI!
Book a free demo
Market is dominated by North America, the clinical adoption has been early, CPC, CMS reimbursement structures have been favourable leading to incorporation of hypo fractionated protocols into the national oncology guidelines.
In the USA, single dose radiotherapy is being increasingly used as an approach to treatment in both early-stage breast cancer post-lumpectomy and bone pain palliation, particularly in a rural and outpatient context. Armed with research on wait-time reduction strategies, Canada currently invests in accelerated access programs for radiotherapy, including one-time treatment options.
Europe is now moving quickly thanks to cost-containment in oncology, EORTC-supported clinical trials and the EU Beating Cancer Plan stimulus, which calls for efficient radiation services. In Germany, UK, France, Italy,
Sweden, single dose radiotherapy is being incorporated for older patients, metastatic alleviation of pain, and specific early cancers. Intraoperative radiotherapy has also begun to be adopted in breast cancer care in specialized centers. The regional emphasis on value-based care and reducing treatment time steps remain prime tailwinds for growth.
Asia-Pacific is the fastest growing region in the global oncology market due to low-growing cancer incidence, growth of public-private oncology infrastructure, and the high demand for accessible radiotherapy services in countries including China, India, Japan, South Korea, and Southeast Asia.
India has government-backed radiotherapy centres deployed and is working on low-cost single dose models, while in China they are investing in smart LINACs as well as rural outreach with mobile radiotherapy units. Precision-guided radiosurgery in one-day protocols dominating in Japan and South Korea, and academic trials focusing on single-session radiotherapy
Equipment Access, Reimbursement Gaps, and Clinical Awareness
While beneficial, widespread implementation is limited by the high upfront costs of radiotherapy systems, inconsistent reimbursement policies, and low physician familiarity with single-dose protocols. For some cancers, long-term efficacy data is still being established, and integration into standard oncology workflows can be challenging.
Furthermore, an exceedingly specific indication patient selection with heavy multidisciplinary coordination and need for sound imaging infrastructure are prevalent.
Hypo-fractionation, AI Planning, and Global Access Models
The movement towards hypo-fractionation and outpatient oncology offers significant growth potential for single dose radiotherapy. More rapid but safe and more effective radiation delivery is becoming possible due to the advances in AI-powered treatment planning, Adaptive Radiotherapy and FLASH.
Mobile radiotherapy services, collaborative oncology networks and remote radiation planning platforms have the potential for scalable solutions in low- and middle-income countries. Market adoption further accelerated by growing clinical guidelines and reimbursement alignment.
In 2020 to 2024, single dose radiotherapy services market gained strong momentum, led by innovation in hypo-fractionated radiation protocols, increasing cancer prevalence, as well as evolving patient preferences for convenient and less intensive treatment regimens.
Single dose radiotherapy particularly intraoperative radiotherapy (IORT) and stereotactic body radiotherapy (SBRT) was adopted for breast, prostate and brain cancers because of its precision and shorter treatment time. But the high price of equipment, the need for specialized expertise, and variations in reimbursement across regions restrict wider adoption.
2025 to 2035: The upscaling of real-time imaging, AI-transverse dosimetry, and smaller, user-friendly delivery systems will expand access to the market. Tailored radiotherapy planning, genomics-linked radiation protocols, and decentralized outpatient delivery models will become standard.
Clinical accuracy, patient safety and cost efficiency will be driven by integration with digital twin models, adaptive radiotherapy platforms and robotic precision systems. Value-based oncology models, government reimbursement reform, and new public hospital-private provider partnerships will enable global expansion.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Approvals for single dose IORT systems in breast cancer; country-specific reimbursement challenges. |
| Technological Innovation | IORT, SBRT, and image-guided radiation systems used for localized tumors. |
| Industry Adoption | Focused on early-stage breast cancer and localized tumors in specialized oncology centers. |
| Smart & AI-Enabled Solutions | Limited to static treatment planning software and image fusion tools. |
| Market Competition | Led by Elekta, Varian (Siemens Healthineers), Xoft (iCAD), and regional oncology service networks. |
| Market Growth Drivers | Reduced patient burden, fewer side effects, and efficiency in high-throughput oncology centers. |
| Sustainability and Environmental Impact | Shift toward outpatient care models with lower facility energy use. |
| Integration of AI & Digitalization | Basic digital recordkeeping and semi-automated planning tools. |
| Advancements in Product Design | Static IORT platforms and fixed radiotherapy suites in tertiary centers. |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Standardized global clinical protocols, bundled payment approvals, and AI-validation frameworks for treatment planning compliance. |
| Technological Innovation | AI-driven adaptive radiotherapy, real-time intra-procedural imaging, and next-gen mobile radiotherapy units for outpatient delivery. |
| Industry Adoption | Expansion into urology, neuro-oncology, and rural/mobile oncology programs using compact systems. |
| Smart & AI-Enabled Solutions | AI-powered dosimetry, predictive toxicity modelling , and digital twin-based simulation for treatment outcome optimization. |
| Market Competition | Intensifying competition from AI-radiotherapy startups, mobile IORT service providers, and integrated oncology care platforms. |
| Market Growth Drivers | Growth driven by aging populations, AI-personalized cancer care, reimbursement reform, and demand for decentralized precision oncology. |
| Sustainability and Environmental Impact | Development of energy-efficient mobile systems, low-radiation waste protocols, and digital reporting to reduce paper-based compliance. |
| Integration of AI & Digitalization | Fully digitized planning-to-delivery pathways, cloud-based treatment management, and remote clinician collaboration platforms. |
| Advancements in Product Design | Portable radiotherapy systems, robotic-guided applicators, and modular treatment units for ambulatory care centers and low-resource settings. |
Hypo-fractionated treatment protocols, as well as favourable reimbursement models, are key drivers in the USA single dose radiotherapy services market, which is experienced moderate growth. Increasing cancer incidence, especially breast and prostate cancers, is fuelling demand for briefer, more efficient treatment regimens.
Top oncology institutions are investing in advanced linear accelerators and IORT equipment that can accommodate single-dose applications. Patient preference for fewer hospital visits and less side effects is also driving adoption. This confidence is continuously validated and reinforced by ongoing clinical trials and evidence-based protocols.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 7.3% |
Single dose radiotherapy services are also a key growth opportunity for the UK cancer market, as the NHS presents a growing agenda around accelerated patient treatment pathways and cost-effective therapies. Recently, single-fraction treatments have gained acceptance among early-stage breast cancer and palliative care regional cancer centers.
The UK-led studies developed by NICE are helping to shape the acceptance of one-off radiotherapy for specific cases. Lower treatment times and reduced hospital burden correspond to the NHS’s strategy of improving capacity further improving patient outcomes.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 6.8% |
The first three countries leading the EU single dose radiotherapy market are Germany, France and the Netherlands, where the integration of this treatment in breast-conserving therapy and managing oligo metastatic disease is progressive. Investment in radiotherapy infrastructure and training, in tandem with streamlined cancer treatment protocols, are driving availability of services.
EU funding for cancer care innovation and cross-border clinical trials where different university hospitals can work together on the same patient types across neighbouring countries is providing further evidence supporting single-dose efficacy for a range of tumor types. There is also increasing demand in outpatient oncology environments trying to maximize efficiency and patient throughput.
| Country | CAGR (2025 to 2035) |
|---|---|
| European Union | 7.0% |
The rising burden of cancer in Japan, together with an aging population, is a prime driver of growth in the single dose radiotherapy services market in the country. Hospitals and cancer centers are integrating single-fraction radiotherapy into breast, liver and bone metastasis treatment.
Japan has a healthcare system that encourages clinical innovation, and it has accepted imaging-guided techniques that improve dose accuracy and outcomes. Patient-centric care models and an impetus to minimize hospital stays is further driving the use of short-course therapies.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.6% |
Rapid dynamics of healthcare infrastructure modernization and rising awareness towards radiotherapy option in the region is driving a fast-growing market for single dose radiotherapy services in South Korea. Some advanced cancer centers including those in Seoul and western cities have embraced this trend with single-fraction stereotactic body radiotherapy (SBRT) and IORT to short cycle treatments and maximize utilization of resources.
The growth of the cerebral spinal fluid (CSF) management market is driven by the government efforts to expand the oncology services and favourable reimbursement landscapes. An FDA/CDC working group has undertaken an initiative to standardize training based on clinical evidence for public and private providers.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 7.5% |
Breast Cancer Leads the Single Dose Radiotherapy Services Market by Indication
| Indication | Value Share (%) |
|---|---|
| Breast Cancer | 55.3% |
By 2025 breast cancer will account for dominant share by value of single dose radiotherapy services (55.3%). This is underpinned by the age-adjusted increasing global prevalence of breast cancer along with earlier clinical adoption of single-dose intraoperative radiotherapy (IORT) as a time-efficient, patient-centred enhancement of conventional multi-session treatments. This treatment is more favourable for early-stage breast cancer patients as single dose radiotherapy shortens overall treatment time and reduces surrounding normal tissue exposure.
Many clinical studies have confirmed the safety and effectiveness of a delivery of a concentrated dose of radiation during surgery, significantly minimizing hospital visits while preserving local control of the tumor. As such, single dose radiotherapy becomes a preferred choice for patients and providers especially in a healthcare system designed to relieve resource strain and improve patient quality of life.
With continued advances of the IORT technology and incorporation of IORT into practice, it demonstrates greater career for breast conserving therapy. Awareness of Treatment Convenience and Favourable Clinical Outcomes to Conceive Breast Cancer Segment to Continue Leading the Overall Single Dose Radiotherapy Services Market. Breast cancer segment is projected to grow at a significant rate, as awareness of treatment convenience and favourable clinical outcomes continue to grow.
External Beam Radiotherapy Dominates the Market by Therapy Type
| Therapy Type | Value Share (%) |
|---|---|
| External Beam Radiotherapy | 60.7% |
EBRT is estimated to account for leading revenue share in the single dose radiotherapy services market, of 60.7% by 2025. The overwhelming majority of patients were treated with external beam radiation therapy (EBRT), which is widely used for local treatment as it is non-invasive and is applicable to a broad range of patients it is also made even more effective due to technological advancements that allow for precise delivery of doses.
It is becoming more and more applied in either curative and palliative settings in oncology, and single-dose EBRT is gaining popularity due to its targeted tumor ablation while limiting the burden of the treatment.
The incorporation of CT and MRI for imaging modalities has led to not only better beam precision, but being able to deliver high-dose radiation to the tumor with minimum influence on surrounding normal tissues. This precision is particularly important in indications like prostate and breast cancer where organ preservation and patient comfort are important.
Moreover, EBRT is backed by a strong infrastructure and is deployable in hospitals and cancer centers all over the world. Advancements in stereotactic body radiotherapy (SBRT) as well as image-guided systems have pushed single dose EBRT into areas that were once difficult to treat.
External beam radiotherapy will continue to be an essential component of single dose cancer treatment facilities worldwide, with increased investment in radiation planning systems, motion management technologies and clinical training.
The growing acceptance of hypo-fractionated treatment regimens among healthcare providers and oncology centers to shorten treatment duration, reduce hospital burden, and alleviate patient stress in breast, prostate, and brain cancers is propelling the growth of single dose radiotherapy services market.
Employing a single high radiation dose session is now attainable owing to the improvement of IGRT (image-guided radiotherapy), stereotactic approaches and targeting of the tumor. Driving factors such as cost-effectiveness, increasing demand for outpatient cancer care, clinical evidence comparing the equivalency in outcomes, and the development of the infrastructure in the emerging oncology hubs are the key market drivers.
Market Share Analysis by Key Players
| Company/Organization Name | Estimated Market Share (%) |
|---|---|
| Varian Medical Systems (Siemens Healthineers) | 18-22% |
| Elekta AB | 14-18% |
| Accuray Incorporated | 11-15% |
| GenesisCare | 8-12% |
| ViewRay Inc. | 6-9% |
| Others | 24-30% |
| Company/Organization Name | Key Offerings/Activities |
|---|---|
| Varian Medical Systems | In 2024, Varian expanded access to HyperArc™ single-fraction stereotactic radiosurgery (SRS) platforms across North America and APAC for outpatient oncology centers. |
| Elekta AB | As of 2023, Elekta integrated Monaco™ treatment planning with Unity MR-Linac , supporting precise tumor targeting for single-dose regimens in soft tissue cancers. |
| Accuray Incorporated | In 2025, Accuray introduced advanced CyberKnife® protocols optimized for single-session treatments in spine, prostate, and intracranial tumors with real-time tracking. |
| GenesisCare | In 2023, GenesisCare launched global centers of excellence offering single-dose breast radiotherapy services , especially post-lumpectomy, aligning with FAST-Forward trial guidelines. |
| ViewRay Inc. | As of 2024, ViewRay enhanced its MRIdian® platform for gated, adaptive single-dose therapy, gaining traction in liver and pancreas tumor treatments. |
Key Market Insights
Varian Medical Systems (18-22%)
Market leader in precision radiotherapy, offering integrated solutions for planning, imaging, and delivery of hypo fractionated and stereotactic treatments across multiple tumor types.
Elekta AB (14-18%)
Strong in MR-guided and real-time adaptive therapy platforms, Elekta supports ultra-precise single-dose workflows in brain and soft tissue oncology.
Accuray Incorporated (11-15%)
Specializes in robotic radiosurgery with sub-millimetre accuracy, widely adopted for single-fraction treatments in hard-to-reach or mobile tumors.
GenesisCare (8-12%)
A global cancer care provider with established outpatient centers focusing on patient-centric, guideline-backed single-dose radiotherapy protocols.
ViewRay Inc. (6-9%)
Pioneer in MR-guided adaptive therapy, providing motion-adaptive, high-precision radiotherapy with growing clinical acceptance for abdominal and thoracic cancers.
Other Key Players (Combined Share: 24-30%)
Several regional hospitals, oncology networks, and private cancer centers are advancing access to single-session radiotherapy through clinical innovation, public-private partnerships, and technology upgrades, including:
The overall market size for the single dose radiotherapy services market was USD 9,072.5 million in 2025.
The single dose radiotherapy services market is expected to reach USD 18,014.4 million in 2035.
The demand for single dose radiotherapy services will be driven by increasing prevalence of cancer, growing preference for minimally invasive and time-efficient treatment options, rising healthcare expenditure, and advancements in precision radiotherapy technologies and treatment planning.
The top 5 countries driving the development of the single dose radiotherapy services market are the USA, Germany, Japan, the UK, and China.
The intraoperative radiotherapy (IORT) segment is expected to command a significant share over the assessment period.
AL Amyloidosis Therapeutics Market Growth and Analysis: 2025 to 2035
Carcinoid Tumor Syndrome Management Market Forecast & Analysis for 2025 to 2035
Cardiogenic Shock Treatment Market Analysis & Forecast for 2025 to 2035
Brain Tumor Drugs Market Forecast & Analysis: 2025 to 2035
Pigmented Lesion Treatment Market Growth - Trends & Forecast 2025 to 2035
The Metered Dose Inhalers Market is Segmented by Type, and End User from 2025 to 2035
Single Dose Radiotherapy Services Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
